Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 21, Issue 5, Pages 295-300
Original Article

A Meta-Analysis of the Success Rate of Helicobacter pylori Therapy in Canada

Christopher Rodgers and Sander Veldhuyzen van Zanten

Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada

Received 22 June 2006; Accepted 12 August 2006

Copyright © 2007 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


BACKGROUND AND AIM: Helicobacter pylori treatment success rates have varied. A systematic review of the success rate of anti-H pylori therapy in Canada was performed.

METHODS: All clinical trials containing Canadian data on the success rate of H pylori treatment were identified using MEDLINE searches, through review of references of retrieved studies and by contacting key investigators. Both randomized and open-label trials were included. Treatment effect size was calculated using a variation of Cochran’s Q method.

RESULTS: Seventeen papers met the inclusion criteria. Both triple therapies consisting of a proton pump inhibitor (PPI), clarithromycin and either amoxicillin or metronidazole performed well, achieving a success rate of 84% and 82%, respectively. The cure rate of PPI-amoxicillin + metronidazole was 76%. Quadruple therapy consisting of a PPI, bismuth, metronidazole and tetracycline, given for seven to 10 days, achieved a success rate of 87%.

CONCLUSION: Both PPI-based triple therapy and quadruple therapy perform well in Canada for the treatment of H pylori infection.